ライフサイエンスコーパス: LVMI

1 LVMI decreased unrelated to HR at baseline (p for intera

2 LVMI was measured by echocardiogram at baseline and at 1

3 is, the RI variability was explained by age, LVMI, and serum phosphate concentration.

4 (LVMI) values, but on multivariate analysis, LVMI correlated with plasma renin activity (p < 0.001) a

5 h smaller LVM (beta: -3.483, P < 0.0001) and LVMI (beta: -0.815, P < 0.0001).

6 ecreased compared with the control group and LVMI was markedly improved by BSJYD treatment in a dose-

7 icant quadratic relationship between Hct and LVMI in premenopausal women (p < 0.01).

8 The mean Hct and LVMI were 46.5% and 41.9%, and 127.3 and 95.8 g/m, respe

9 ference between groups for change in LVM and LVMI was -3.89 g (95% confidence interval: -1.1 to -6.7)

10 nterrelationsh between kidney morphology and LVMI indicates that such associations may be a biologica

11 y than atenolol with adjustment for baseline LVMI and blood pressure and in-treatment pressure (-21.7

12 ADC (Spearman = 0.450, p < 0.05) and between LVMI and ECV (Spearman = 0.181, p < 0.05).

13 Positive associations were noted between LVMI and ADC (Spearman = 0.450, p < 0.05) and between LV

14 uding baseline differences in LVMI, and both LVMI and LA volume conferred additional prognostic infor

15 s significantly more effective in decreasing LVMI (P < 0.01).

16 Greater LVMI reduction with losartan was observed in women and m

17 in men and a small but significantly higher LVMI in men and postmenopausal women.

18 Changes in LVMI measured by cardiovascular MR (n=38) were consisten

19 There were no significant changes in LVMI, CRP, or erythropoietin resistance index in the con

20 lysis patients experienced a 30% decrease in LVMI (154 +/- 33 to 108 +/- 25; P < 0.0001).

21 .12, P = 0.04) predicted a 12-mo decrease in LVMI.

22 enuated by including baseline differences in LVMI, and both LVMI and LA volume conferred additional p

23 n-based therapy induced greater reduction in LVMI from baseline to the last available study than aten

24 aller LV and larger LA volumes and increased LVMI.

25 o -1.3 +/- 4.48 g; p = 0.007) and LVM index (LVMI) (allopurinol -2.2 +/- 2.78 g/m(2) vs. placebo -0.5

26 left ventricular mass (LVM), and LVM index (LVMI) increased in subsequent RI quartile subgroups.

27 ) BP control on left ventricular mass index (LVMI) and kidney function in 75 hypertensive ADPKD patie

28 ocrit (Hct) and left ventricular mass index (LVMI) and LV hypertrophy (LVH) in subjects without known

29 umes and higher left ventricular mass index (LVMI) and LV mass/LV volume ratio.

30 Left ventricular mass index (LVMI) correlated to the same extent with central and per

31 In all SBP tertiles, LV mass index (LVMI) decreased similarly (LVMI -6.3 +/- 2.2 g/m(2.7), -

32 e was change in left ventricular mass index (LVMI) measured by transthoracic echocardiography and, in

33 nts had greater left ventricular mass index (LVMI) values, but on multivariate analysis, LVMI correla

34 pathology, and left ventricular mass index (LVMI) were measured.

35 r =1 follow-up measurement of LV mass index (LVMI) were used in an intention-to-treat analysis.

36 We measured left ventricular mass index (LVMI) with cardiac magnetic resonance imaging (MRI), ass

37 used to measure left ventricular mass index (LVMI), cardiac index (CI), and stroke volume index (SVI)

38 thickness, LV mass (LVM), and LV mass index (LVMI), compared to participants in 7-9 h/night or >9 h/n

39 hocardiographic left ventricular mass index (LVMI), serum C-reactive protein (CRP), serum calcium and

40 rrelation was found between RI and age, LVM, LVMI, and plasma parathormone concentration and was nega

41 ct was associated with a 2.6 g/m higher mean LVMI in men, and a 1.8 g/m higher mean LVMI in postmenop

42 mean LVMI in men, and a 1.8 g/m higher mean LVMI in postmenopausal women (p < 0.05).

43 here were no significant differences in mean LVMI between the stentless versus stented groups at base

44 s, LV mass index (LVMI) decreased similarly (LVMI -6.3 +/- 2.2 g/m(2.7), -8.3 +/- 2.1 g/m(2.7), and -

45 The results showed that LVMI of patients treated with troglitazone was not stati

46 The LVMI decreased by 21% in the standard group and by 35% i

47 inal fat correlated to a similar extent with LVMI.

48 to evaluate the association between Hct with LVMI and LVH.

49 ing could be an association between Hct with LVMI or LVH.

50 associated inversely and independently with LVMI.